Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda to Acquire LigoCyte | Contract Pharma

What are you searching for?

Sign in
Breaking News

Takeda to Acquire LigoCyte

Expands vaccine portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda America Holdings, Inc., a subsidiary of Takeda Pharmaceutical Co., will acquire LigoCyte Pharmaceuticals for an upfront payment of $60 million, with future payments based on the progress of development projects. LigoCyte is a privately held biopharma company specializing in vaccine products, and is headquartered in Bozeman, MT. Its lead vaccine product to prevent norovirus gastroenteritis is in Phase I/II development. LigoCyte has also initiated preclinical development of vaccines against respiratory syncytial virus, influenza and rotavirus.
 
“Takeda’s acquisition of LigoCyte is a major step forward in the expansion of Takeda’s vaccine business, and a demonstration of Takeda’s dedication to preventing illness in children and adults around the world,” said Rajeev Venkayya, M.D., executive vice president of Takeda’s Vaccine Business Division (VBD), which was launched in January 2012. “Norovirus is the most common cause of outbreaks of gastroenteritis and foodborne illness in the U.S., and is responsible for 200,000 deaths each year, most of them in developing countries. With the only norovirus vaccine in clinical trials today, Takeda will be in a position to change this picture.”
 
Takeda will continue operating LigoCyte in Bozeman and plans to retain the management team and its employees. Mr. Beeman and his management team will become a part of Takeda’s Vaccine Business Division.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics